secwatch.observer — SEC 8-K summary
======================================

Issuer:     Roivant Sciences Ltd. (ROIV)
CIK:        0001635088
Form:       8-K
Filed at:   2025-09-03T23:59:59+00:00
Accession:  0001140361-25-033767
Event type: other_material
Sentiment:  positive
Materiality: 0.80
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Roivant reports ~80% durability and ~50% ATD-free remission in Graves' disease data
--------------------------------------------------------------------------------

- Of 21 patients in 6-month off-treatment follow-up, ~80% (17/21) maintained normal thyroid function.
- ~50% of responders (8/17) achieved anti-thyroid drug-free remission after 6 months off batoclimab.
- Two registrational trials for IMVT-1402 in Graves' disease are enrolling; topline data expected 2027.
- Safety consistent with prior batoclimab studies; first potential disease-modifying therapy for uncontrolled GD.
- Roivant and Immunovant to host investor call Sept 3, 2025 at 4:30 p.m. EDT to discuss data.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1635088/000114036125033767/0001140361-25-033767-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1635088/000114036125033767/ef20055076_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-25-033767

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer